Intel (INTC) 10-Q 25 Apr 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares shares in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 19, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 30, 2024
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	(408)
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,257

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Income Statement [Abstract]
Net revenue	$ 12,724	$ 11,715
Cost of sales	7,507	7,707
Gross margin	5,217	4,008
Research and development	4,382	4,109
Marketing, general, and administrative	1,556	1,303
Restructuring and other charges	348	64
Operating expenses	6,286	5,476
Operating income (loss)	(1,069)	(1,468)
Gains (losses) on equity investments, net	205	169
Interest and other, net	145	141
Income (loss) before taxes	(719)	(1,158)
Provision for (benefit from) taxes	(282)	1,610
Net income (loss)	(437)	(2,768)
Less: Net income (loss) attributable to non-controlling interests	(56)	(10)
Net income (loss) attributable to Intel	$ (381)	$ (2,758)
Earnings per share - Basic (in dollars per share)	$ (0.09)	$ (0.66)
Earnings per share - Diluted (in dollars per share)	$ (0.09)	$ (0.66)
Weighted average shares of common stock outstanding:
Basic (shares)	4,242	4,154
Diluted (shares)	4,242	4,154

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (437)	$ (2,768)
Changes in other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(328)	142
Actuarial valuation and other pension benefits (expenses), net	0	1
Translation adjustments and other	1	0
Other comprehensive income (loss)	(327)	143
Total comprehensive income (loss)	(764)	(2,625)
Less: comprehensive income (loss) attributable to non-controlling interests	(56)	(10)
Total comprehensive income (loss)	$ (708)	$ (2,615)

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents	$ 6,923	$ 7,079
Short-term investments	14,388	17,955
Accounts receivable, net	3,323	3,402
Inventories	11,494	11,127
Other current assets	6,480	3,706
Total current assets	42,608	43,269
Property, plant, and equipment, net of accumulated depreciation of $99,315 ($98,010 as of December 30, 2023)	99,924	96,647
Equity Investments	6,139	5,829
Goodwill	27,440	27,591
Identified intangible assets, net	4,675	4,589
Other long-term assets	11,947	13,647
Total assets	192,733	191,572
Current liabilities:
Short-term debt	4,581	2,288
Accounts payable	8,559	8,578
Accrued compensation and benefits	2,506	3,655
Income taxes payable	346	1,107
Other accrued liabilities	11,221	12,425
Total current liabilities	27,213	28,053
Debt	47,869	46,978
Other long-term liabilities	6,895	6,576
Contingencies (Note 13)
Stockholders’ equity:
Common stock and capital in excess of par value, 4,257 issued and outstanding (4,228 issued and outstanding as of December 30, 2023)	38,291	36,649
Accumulated other comprehensive income (loss)	(542)	(215)
Retained earnings	68,224	69,156
Total stockholders' equity	105,973	105,590
Non-controlling interest	4,783	4,375
Accumulated other comprehensive income (loss)	110,756	109,965
Total liabilities and stockholders’ equity	$ 192,733	$ 191,572

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Assets
Accumulated depreciation	$ 99,315	$ 98,010
Stockholders’ equity:
Common stock, shares issued	4,257	4,228
Common stock, shares outstanding	4,257	4,228

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 7,079	$ 11,144
Cash flows provided by (used for) operating activities:
Net income (loss)	(437)	(2,768)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	2,200	1,901
Share-based compensation	1,179	739
Restructuring and other charges	348	55
Amortization of intangibles	351	465
(Gains) losses on equity investments, net	(208)	(167)
Changes in assets and liabilities:
Accounts receivable	80	286
Inventories	(366)	231
Accounts payable	(386)	(771)
Accrued compensation and benefits	(1,289)	(1,560)
Income taxes	(591)	1,344
Other assets and liabilities	(2,104)	(1,540)
Total adjustments	(786)	983
Net cash provided by operating activities	(1,223)	(1,785)
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(5,970)	(7,413)
Proceeds from capital-related government incentives	592	0
Purchases of short-term investments	(6,460)	(16,132)
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	9,598	14,173
Other investing	(323)	851
Net cash used for investing activities	(2,563)	(8,521)
Cash flows provided by (used for) financing activities:
Issuance of commercial paper, net of issuance costs	793	0
Repayment of commercial paper	0	(2,930)
Payments on finance leases	0	(15)
Partner contributions	423	449
Issuance of long-term debt, net of issuance costs	2,537	10,968
Proceeds from sales of common stock through employee equity incentive plans	626	659
Payment of dividends to stockholders	(529)	(1,512)
Other financing	(220)	(225)
Net cash provided by (used for) financing activities	3,630	7,394
Net increase (decrease) in cash and cash equivalents	(156)	(2,912)
Cash and cash equivalents, end of period	6,923	8,232
Supplemental disclosures:
Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities	5,167	4,711
Interest, net of capitalized interest	540	239
Income taxes, net of refunds	$ 315	$ 267

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock and Capital in Excess of Par Value	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interest
Common stock, shares outstanding, beginning (in shares) at Dec. 31, 2022		4,137
Total stockholders' equity, beginning at Dec. 31, 2022	$ 103,286	$ 31,580	$ (562)	$ 70,405	$ 1,863
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(2,768)			(2,758)	(10)
Other comprehensive income (loss)	143		143
Net proceeds from partner contributions	449				449
Employee equity incentive plans and other (in shares)		36
Employee equity incentive plans and other	659	$ 659
Share-based compensation	739	$ 697			42
Restricted stock unit withholdings (in shares)		(2)
Restricted stock unit withholdings	(69)	$ (107)		38
Cash dividends declared	(2,036)			(2,036)
Common stock, shares outstanding, ending (in shares) at Apr. 01, 2023		4,171
Total stockholders' equity, ending at Apr. 01, 2023	$ 100,403	$ 32,829	(419)	65,649	2,344
Common stock, shares outstanding, beginning (in shares) at Dec. 30, 2023	4,228	4,228
Total stockholders' equity, beginning at Dec. 30, 2023	$ 109,965	$ 36,649	(215)	69,156	4,375
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(437)			(381)	(56)
Other comprehensive income (loss)	(327)		(327)
Net proceeds from partner contributions	423	$ 0			423
Employee equity incentive plans and other (in shares)		32
Employee equity incentive plans and other	626	$ 626
Share-based compensation	1,179	$ 1,138			41
Restricted stock unit withholdings (in shares)		(3)
Restricted stock unit withholdings	(144)	$ (122)		(22)
Cash dividends declared	$ (529)			(529)
Common stock, shares outstanding, ending (in shares) at Mar. 30, 2024	4,257	4,257
Total stockholders' equity, ending at Mar. 30, 2024	$ 110,756	$ 38,291	$ (542)	$ 68,224	$ 4,783

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Retained Earnings
Cash dividends declared (in dollars per share)	$ 0.13	$ 0.49

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 : Basis of Presentation We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2023 Form 10-K. We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with our 2023 Form 10-K where we include additional information on our critical accounting estimates, policies, and the methods and assumptions used in our estimates.

Operating Segments

Operating Segments	3 Months Ended
	Mar. 30, 2024
Segment Reporting [Abstract]
Operating Segments	Note 2 : Operating Segments We previously announced the implementation of our internal foundry operating model, which took effect in the first quarter of 2024, and creates a foundry relationship between our Intel Products business (collectively CCG, DCAI, and NEX) and our Intel Foundry business. Intel Products consists substantially of design and development of CPUs and related solutions for third party customers. Intel Foundry consists substantially of process engineering, manufacturing, and foundry services groups that provide manufacturing, test, and assembly services to our Intel Products business and to third party customers. Both businesses utilize marketing, sales, and other support functions. Our internal foundry model is a key component of our strategy and is designed to reshape our operational dynamics and drive greater transparency, accountability, and focus on costs and efficiency. We also previously announced our intent to operate Altera, an Intel Company (previously Intel's Programmable Solutions Group), as a standalone business, with segment reporting beginning in the first quarter of 2024. Altera was previously included in our DCAI segment results. As a result of these changes, we modified our segment reporting in the first quarter of 2024 to align to this new operating model. All prior period segment data has been retrospectively adjusted to reflect the way our Chief Operating Decision Maker (CODM) internally receives information and manages and monitors our operating segment performance starting in fiscal year 2024. There are no changes to our consolidated financial statements for any prior periods. We organize our business as follows: ▪ Intel Products: ▪ C lient Computing Group (CCG) ▪ Data Center and AI (DCAI) ▪ Network and Edge (NEX) ▪ Intel Foundry ▪ All other ▪ A ltera ▪ M obileye ▪ Other CCG, DCAI, and Intel Foundry qualify as reportable operating segments. NEX, Altera, and Mobileye do not qualify as reportable operating segments; however, we have elected to disclose their results. When we enter into federal contracts, they are aligned to the sponsoring operating segment. The accounting policies for our segment reporting are the same for Intel as a whole. A summary of the basis for which we report our operating segment revenues and operating margin is as follows: Intel Products: CCG, DCAI, and NEX ▪ Segment revenue: consists of revenues from third party customers. The Intel Products operating segments represent a substantial majority of Intel consolidated revenue and are derived from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which are based on Intel architecture. ▪ Segment expenses: consists of intersegment charges for product manufacturing and related services from Intel Foundry, external foundry and other manufacturing, product development costs, allocated expenses as described below, and direct operating expenses. Intel Foundry ▪ Segment revenue : consists substantially of intersegment product and services revenue for wafer fabrication and related products and services sold to Intel Products, Altera, and certain other Intel internal businesses. We recognize intersegment revenue when we satisfy performance obligations as evidenced by the transfer of control of Intel Foundry products and services to the Intel Products businesses, which is generally at the completion of wafer sorting and at the completion of assembly and test services. Intersegment sales are recorded at prices that are intended to approximate market pricing. Intel Foundry also includes certain third party foundry and assembly and test revenues from external customers that were $27 million in first three months of 2024 and $118 million in the first three months of 2023. ▪ Segment expenses: consists of direct expenses for technology development, product manufacturing and services provided by Intel Foundry to internal and external customers, allocated expenses as described below, and direct operating expenses. Direct expenses for product manufacturing includes excess capacity charges that were previously allocated primarily to CCG, DCAI, and NEX. All other: Altera & Mobileye ▪ Segment revenue: consists of product revenues from third party customers. Altera revenue is derived from programmable semiconductors, primarily FPGAs, CPLDs, acceleration platforms, software, IP, and related products. Mobileye revenue is derived from advanced driver-assistance systems (ADAS) and autonomous driving technologies and solutions. ▪ Segment expenses: Altera expenses consist of intersegment charges for product manufacturing and related services from Intel Foundry, third party manufacturing, allocated expenses as described below, and direct operating expenses. Mobileye expenses consists of third party direct expenses for product manufacturing and related services for the manufacturing of Mobileye products and direct operating expenses. Our "all other" category also consists of "other", which includes: ▪ results of operations from non-reportable segments not otherwise presented, and from start-up businesses that support our initiatives; and ▪ historical results of operations from divested businesses. We allocate operating expenses from our sales and marketing group to the Intel Products operating segments, and allocate operating expenses from our finance and administration groups to all of our operating segments, except Mobileye. Previously, operating expense from all of these groups as well as manufacturing and engineering, were generally allocated to all the operating segments, except Mobileye. We estimate that the substantial majority of our consolidated depreciation expense was incurred by Intel Foundry in the first three months of 2024 and in the first three months of 2023. Intel Foundry depreciation expense is substantially included in overhead cost pools and then combined with other costs, and subsequently absorbed into inventory as each product passes through the manufacturing process and is sold to Intel Products and other customers. As a result, it is impractical to determine the total depreciation expense included as a component of each Intel Products operating segment's operating income (loss) results. We do not allocate to our operating segments corporate operating expenses that primarily consist of: ▪ restructuring and other charges; ▪ share-based compensation; ▪ certain impairment charges; and ▪ certain acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. We do not allocate to our operating segments non-operating items such as: ▪ gains and losses from equity investments; ▪ interest and other income; and ▪ income taxes. The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). Although the CODM uses operating income (loss) to evaluate the segments, operating costs included in one segment may benefit other segments. The measures regularly provided to and used by our CODM under our new operating model continue to evolve; currently, our CODM does not regularly review or receive discrete asset information by segment. Intersegment eliminations: Intersegment sales and related gross margin on inventory recorded at the end of the period or sold through to third party customers is eliminated for consolidation purposes. The Intel Products operating segments and Intel Foundry are meant to reflect separate fabless semiconductor and foundry companies. Thus certain intersegment activity is captured within the intersegment eliminations upon consolidation and presented at the Intel consolidated level. This activity primarily relates to inventory reserves which are determined and recorded based on our accounting policies for Intel as a whole, but are only recorded by the Intel Products operating segments upon transfer of inventory from Intel Foundry. If a reserve is identified prior to the related inventory transferring to Intel Products, that reserve is presented as activity within the intersegment eliminations. Reporting units and goodwill reallocation: As a result of modifying our segment reporting in the first quarter of 2024, we reallocated goodwill among our affected reporting units on a relative fair value basis. We performed a quantitative goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization. We concluded based on our pre-reorganization impairment test that goodwill was not impaired. As a result of our post-reorganization impairment test, we recognized a non-cash goodwill impairment loss of $222 million in the first three months of 2024 related to our new Intel Foundry reporting unit as the estimated fair value of the new reporting unit was lower than the assigned carrying value, which now includes substantially all of our allocated property, plant, and equipment. The Intel Foundry reporting unit has no remaining goodwill. The fair value substantially exceeded the carrying value for all remaining reporting units tested as part of our post-reorganization impairment test. Operating segment and consolidated net revenue and operating income (loss) for each period were as follows: Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Operating segment revenue: Intel Products: Client Computing Group Desktop $ 2,461 $ 1,879 Notebook 4,681 3,407 Other 391 481 7,533 5,767 Data Center and AI 3,036 2,901 Network and Edge 1,364 1,489 Total Intel Products revenue $ 11,933 $ 10,157 Intel Foundry $ 4,369 $ 4,831 All other Altera 342 816 Mobileye 239 458 Other 194 166 Total all other revenue 775 1,440 Total operating segment revenue $ 17,077 $ 16,428 Intersegment eliminations (4,353) (4,713) Total net revenue $ 12,724 $ 11,715 Segment operating income (loss): Intel Products: Client Computing Group $ 2,645 $ 1,180 Data Center and AI 482 22 Network and Edge 184 (69) Total Intel Products operating income (loss) $ 3,311 $ 1,133 Intel Foundry $ (2,474) $ (2,360) All Other Altera (39) 290 Mobileye (68) 123 Other (105) (66) Total all other operating income (loss) (212) 347 Total segment operating income (loss) $ 625 $ (880) Intersegment eliminations 494 456 Corporate unallocated expenses (2,188) (1,044) Total operating income (loss) $ (1,069) $ (1,468) Corporate Unallocated Expenses Corporate unallocated expenses represent costs incurred that are not directly attributed to an operating segment. The nature of these expenses may vary, but primarily consist of restructuring and other charges, share-based compensation, certain impairment charges, and certain acquisition-related costs. Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Acquisition-related adjustments $ (265) $ (371) Share-based compensation (1,179) (739) Restructuring and other charges (348) (64) Other (396) 130 Total corporate unallocated expenses $ (2,188) $ (1,044)

Non-Controlling Interests

Non-Controlling Interests	3 Months Ended
	Mar. 30, 2024
Noncontrolling Interest [Abstract]
Non-Controlling Interests	Note 3 : Non-Controlling Interests Mar 30, 2024 Dec 30, 2023 (In Millions) Non-Controlling Interests Non-Controlling Ownership % Non-Controlling Interests Non-Controlling Ownership % Arizona Fab LLC $ 2,760 49 % $ 2,359 49 % Mobileye 1,854 12 % 1,838 12 % IMS Nanofabrication 169 32 % 178 32 % Non-controlling interests $ 4,783 $ 4,375 Semiconductor Co-Investment Program In 2022, we closed a transaction with Brookfield Asset Management (Brookfield) resulting in the formation of Arizona Fab LLC (Arizona Fab). We consolidate the results of Arizona Fab, a VIE, into our consolidated financial statements because we are the primary beneficiary. Generally, contributions will be made to, and distributions will be received from Arizona Fab based on both parties' proportional ownership. We will be the sole operator and main beneficiary of two new chip factories that will be constructed by Arizona Fab, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to operate Arizona Fab at minimum production levels measured in wafer starts per week and will be required to limit excess inventory held on site or we will be subject to certain penalties. We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona Fab of $29.0 billion. As of March 30, 2024, substantially all of the assets of Arizona Fab consisted of property, plant, and equipment. The assets held by Arizona Fab, which can be used only to settle obligations of the VIE and are not available to us, were $5.6 billion as of March 30, 2024 ($4.8 billion as of December 30, 2023). Mobileye In 2022, Mobileye completed its IPO and certain other equity financing transactions. During 2023, we converted 38.5 million of our Mobileye Class B shares into Class A shares, representing 5% of Mobileye's outstanding capital stock, and subsequently sold the Class A shares for $42 per share as part of a secondary offering, receiving net proceeds of $1.6 billion and increasing our capital in excess of par value by $663 million, net of tax. We continue to consolidate the results of Mobileye into our consolidated financial statements. IMS Nanofabrication

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 4 : Earnings (Loss) Per Share We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Three Months Ended (In Millions, Except Per Share Amounts) Mar 30, 2024 Apr 1, 2023 Net income (loss) $ (437) $ (2,768) Less: Net income (loss) attributable to non-controlling interests (56) (10) Net income (loss) attributable to Intel (381) (2,758) Weighted average shares of common stock outstanding—basic 4,242 4,154 Weighted average shares of common stock outstanding—diluted 4,242 4,154 Earnings (loss) per share attributable to Intel—basic $ (0.09) $ (0.66) Earnings (loss) per share attributable to Intel—diluted $ (0.09) $ (0.66) Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. Due to our net losses in the three months ended March 30, 2024 and April 1, 2023, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan had an anti-dilutive effect on diluted loss per share for the period and were excluded from the computation of diluted loss per share.

Other Financial Statement Detai

Other Financial Statement Details	3 Months Ended
	Mar. 30, 2024
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 5 : Other Financial Statement Details Accounts Receivable We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $500 million during the first three months of 2024 ($500 million in the first three months of 2023). After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution. Inventories (In Millions) Mar 30, 2024 Dec 30, 2023 Raw materials $ 1,209 $ 1,166 Work in process 6,560 6,203 Finished goods 3,725 3,758 Total inventories $ 11,494 $ 11,127 Other Accrued Liabilities Other accrued liabilities include deferred compensation of $2.9 billion as of March 30, 2024 ($2.9 billion as of December 30, 2023). Interest and Other, Net Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Interest income $ 323 $ 334 Interest expense (258) (193) Other, net 80 — Total interest and other, net $ 145 $ 141 Interest expense is net of $363 million of interest capitalized in the first three months of 2024 ($363 million in the first three months of 2023).

Restructuring and Other Charges

Restructuring and Other Charges	3 Months Ended
	Mar. 30, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Note 6 : Restructuring and Other Charges Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Employee severance and benefit arrangements $ 129 $ (39) Litigation charges and other — 77 Asset impairment charges 219 26 Total restructuring and other charges $ 348 $ 64 Employee severance and benefit arrangements includes a charge of $129 million in the first quarter of 2024 relating to actions taken to streamline operations and to reduce costs. We expect these actions to be substantially completed by the third quarter of 2024, but this is subject to change. Any changes to the estimates or timing will be reflected in our results of operations. Asset impairment charges includes a goodwill impairment loss of $222 million in the first quarter of 2024 related to our new Intel Foundry reporting unit. Refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for further information on our business reorganization and goodwill impairment.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 : Income Taxes Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Income (loss) before taxes $ (719) $ (1,158) Provision for (benefit from) taxes $ (282) $ 1,610 Effective tax rate 39.2 % (139.0) % Our provision for, or benefit from, income taxes for an interim period has historically been determined using an estimated annual effective tax rate, adjusted for discrete items, if any. Under certain circumstances where we are unable to make a reliable estimate of the annual effective tax rate, we use the actual effective tax rate for the year-to-date period. During the first quarter of 2024, we used the actual effective tax rate approach due to the variability of the rate as a result of fluctuations in forecasted income and the effects of being taxed in multiple tax jurisdictions.

Investments

Investments	3 Months Ended
	Mar. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investments	Note 8 : Investments Short-term Investments Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within cash and cash equivalents and short-term investments on the Consolidated Condensed Balance Sheets . Government debt includes instruments such as non-US government bills and bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of March 30, 2024, and December 30, 2023, substantially all time deposits were issued by institutions outside the US. For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in interest and other, net . The fair value of our hedged investments was $13.8 billion as of March 30, 2024 ($17.1 billion as of December 30, 2023). For hedged investments still held at the reporting date, we recorded net losses of $307 million in the first three months of 2024 ($90 million of net gains in the first three months of 2023). We recorded net gains on the related derivatives of $345 million in the first three months of 2024 ($102 million of net losses in the first three months of 2023). Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) and realized gains or losses recorded in interest and other, net . The adjusted cost of our unhedged investments was $4.0 billion as of March 30, 2024 ($4.7 billion as of December 30, 2023), which approximated the fair value for these periods. The fair value of marketable debt investments, by contractual maturity, as of March 30, 2024, was as follows: (In Millions) Fair Value Due in 1 year or less $ 5,579 Due in 1–2 years 2,457 Due in 2–5 years 6,915 Due after 5 years 433 Instruments not due at a single maturity date 1 2,460 Total $ 17,844 1 Instruments not due at a single maturity date is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents. Equity Investments (In Millions) Mar 30, 2024 Dec 30, 2023 Marketable equity securities 1 $ 1,471 $ 1,194 Non-marketable equity securities 4,664 4,630 Equity method investments 4 5 Total $ 6,139 $ 5,829 1 Approximately 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange. The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Ongoing mark-to-market adjustments on marketable equity securities $ (91) $ 188 Observable price adjustments on non-marketable equity securities 24 10 Impairment charges (69) (36) Sale of equity investments and other 1 341 7 Total gains (losses) on equity investments, net $ 205 $ 169 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions.

Divestitures

Divestitures	3 Months Ended
	Mar. 30, 2024
Business Combinations [Abstract]
Divestitures	Note 9 : Divestitures NAND Memory Business The NAND memory business included our NAND memory technology and manufacturing business (the NAND OpCo Business), which we deconsolidated upon closing the first phase of our sale agreement with SK hynix Inc (SK hynix) on December 29, 2021. We have a receivable within other current assets for the remaining proceeds of $2.0 billion, which remains outstanding as of March 30, 2024 and will be received upon the second closing of the transaction, expected to be in March 2025. The wafer manufacturing and sale agreement includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to $500 million annually, and $1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics. We were reimbursed for costs that we incurred on behalf of the NAND OpCo Business for corporate function services, which include human resources, information technology, finance, supply chain, and other compliance requirements. We recorded a receivable related to these reimbursable costs due from the NAND OpCo Business, a deconsolidated entity, of $150 million within other current assets as of March 30, 2024 ($145 million recorded as of December 30, 2023).

Borrowings

Borrowings	3 Months Ended
	Mar. 30, 2024
Debt Disclosure [Abstract]
Borrowings	Note 10 : Borrowings In the first quarter of 2024, we issued a total of $2.6 billion aggregate principal amount of senior notes. We also expanded both our 5-year $5.0 billion revolving credit facility agreement and our 364-day $5.0 billion credit facility agreement, to $7.0 billion and $8.0 billion, respectively, and the maturity dates were extended by one year to February 2029 and January 2025, respectively. The revolving credit facilities had no borrowings outstanding as of March 30, 2024. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. We had $793 million of commercial paper outstanding as of March 30, 2024 (no commercial paper outstanding as of December 30, 2023). Our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our senior fixed rate notes rank equally in the right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries.

Fair Value

Fair Value	3 Months Ended
	Mar. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 11 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Mar 30, 2024 Dec 30, 2023 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 231 $ — $ 231 $ — $ 769 $ — $ 769 Financial institution instruments¹ 2,438 787 — 3,225 2,241 835 — 3,076 Reverse repurchase agreements — 2,370 — 2,370 — 2,554 — 2,554 Short-term investments: Corporate debt — 6,298 — 6,298 — 6,951 — 6,951 Financial institution instruments¹ 22 3,777 — 3,799 33 4,215 — 4,248 Government debt² — 4,291 — 4,291 — 6,756 — 6,756 Other current assets: Derivative assets 34 739 — 773 366 809 — 1,175 Marketable equity securities 1,471 — — 1,471 1,194 — — 1,194 Other long-term assets: Derivative assets — 6 — 6 — 21 — 21 Total assets measured and recorded at fair value $ 3,965 $ 18,499 $ — $ 22,464 $ 3,834 $ 22,910 $ — $ 26,744 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 375 $ 118 $ 493 $ — $ 541 $ 99 $ 640 Other long-term liabilities: Derivative liabilities — 611 — 611 — 479 — 479 Total liabilities measured and recorded at fair value $ — $ 986 $ 118 $ 1,104 $ — $ 1,020 $ 99 $ 1,119 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, commercial paper, notes and bonds issued by financial institutions. 2 Level 2 investments consist primarily of non-US government debt. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets—such as intangible assets, goodwill, and property, plant, and equipment—are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, certain other receivables, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of March 30, 2024 was $666 million (the aggregate carrying value as of December 30, 2023 was $559 million).

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 12 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Mar 30, 2024 Dec 30, 2023 Foreign currency contracts $ 27,942 $ 30,064 Interest rate contracts 18,611 18,363 Other 2,507 2,103 Total $ 49,060 $ 50,530 The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of March 30, 2024 and December 30, 2023. Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Mar 30, 2024 Dec 30, 2023 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 69 $ 307 $ 255 $ 142 Interest rate contracts — 723 — 578 Total derivatives designated as hedging instruments $ 69 $ 1,030 $ 255 $ 720 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 391 $ 65 $ 314 $ 363 Interest rate contracts 285 9 261 36 Equity contracts 34 — 366 — Total derivatives not designated as hedging instruments $ 710 $ 74 $ 941 $ 399 Total derivatives $ 779 $ 1,104 $ 1,196 $ 1,119 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Condensed Balance Sheets Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Mar 30, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 632 $ — $ 632 $ (350) $ (282) $ — Reverse repurchase agreements 2,370 — 2,370 — (2,370) — Total assets $ 3,002 $ — $ 3,002 $ (350) $ (2,652) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,097 $ — $ 1,097 $ (350) $ (620) $ 127 Total liabilities $ 1,097 $ — $ 1,097 $ (350) $ (620) $ 127 Dec 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to cash flow hedges recognized in other comprehensive income (loss) were $431 million net loss in the first three months of 2024 ($53 million net gains in the first three months of 2023). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented. During the first three months of 2024 and 2023, the amounts excluded from effectiveness testing were insignificant. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Interest rate contracts $ (144) $ 192 Hedged items 144 (192) Total $ — $ — The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Mar 30, 2024 Dec 30, 2023 Mar 30, 2024 Dec 30, 2023 Long-term debt $ (11,275) $ (11,419) $ 722 $ 578 Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended (In Millions) Location of Gains (Losses) Mar 30, 2024 Apr 1, 2023 Foreign currency contracts Interest and other, net $ 346 $ 1 Interest rate contracts Interest and other, net 117 (34) Other Various 137 115 Total $ 600 $ 82

Contingencies

Contingencies	3 Months Ended
	Mar. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 13 : Contingencies Legal Proceedings We are regularly party to various ongoing claims, litigation, and other proceedings, including those noted in this section. We have accrued a charge of $1.0 billion related to litigation involving VLSI and a charge of $401 million related to an EC-imposed fine, both as described below. Excluding the VLSI claims, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings, excessive verdicts, or other events could occur. Unfavorable resolutions could include substantial monetary damages, fines, or penalties. Certain of these outstanding matters include speculative, substantial, or indeterminate monetary awards. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Unless specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. European Commission Competition Matter In 2009, the EC found that we had used unfair business practices to persuade customers to buy microprocessors in violation of Article 82 of the EC Treaty (later renumbered Article 102) and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 by offering alleged “conditional rebates and payments” that required customers to purchase all or most of their x86 microprocessors from us and by making alleged “payments to prevent sales of specific rival products.” The EC ordered us to end the alleged infringement referred to in its decision and imposed a €1.1 billion fine, which we paid in the third quarter of 2009. We appealed the EC decision to the European Court of Justice in 2014, after the General Court (then called the Court of First Instance) rejected our appeal of the EC decision in its entirety. In September 2017, the Court of Justice sent the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. In January 2022, the General Court annulled the EC’s 2009 findings against us regarding rebates, as well as the €1.1 billion fine imposed on Intel, which was returned to us in February 2022. The General Court’s January 2022 decision did not annul the EC’s 2009 finding that we made payments to prevent sales of specific rival products. In April 2022 the EC appealed the General Court’s decision to the Court of Justice. In addition, in September 2023 the EC imposed a €376 million ($401 million) fine against us based on its finding that we made payments to prevent sales of specific rival products. We have appealed the EC’s decision. We have accrued a charge for the fine and are unable to make a reasonable estimate of the potential loss or range of losses in excess of this amount given the procedural posture and the nature of these proceedings. In a related matter, in April 2022 we filed applications with the General Court seeking an order requiring the EC to pay us approximately €593 million in default interest on the original €1.1 billion fine that was held by the EC for 12 years, which applications have been stayed pending the EC’s appeal of the General Court’s January 2022 decision. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified Intel and other companies that it had identified security vulnerabilities, the first variants of which are now commonly referred to as “Spectre” and “Meltdown,” that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. In January 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. As of April 24, 2024, consumer class action lawsuits against us were pending in the US and Canada. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by our actions and/or omissions in connection with Spectre, Meltdown, and other variants of this class of security vulnerabilities that have been identified since 2018, and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the US, class action suits filed in various jurisdictions between 2018 and 2021 were consolidated for all pretrial proceedings in the US District Court for the District of Oregon, which entered final judgment in favor of Intel in July 2022 based on plaintiffs’ failure to plead a viable claim. The Ninth Circuit Court of Appeals affirmed the district court’s judgment in November 2023, ending the litigation. In November 2023, new plaintiffs filed a consumer class action complaint in the US District Court for the Northern District of California with respect to a further vulnerability variant disclosed in August 2023 and commonly referred to as “Downfall.” We moved to dismiss that complaint in January 2024. In Canada, an initial status conference has not yet been scheduled in one case relating to Spectre and Meltdown pending in the Superior Court of Justice of Ontario, and a stay of a second case pending in the Superior Court of Justice of Quebec is in effect. In a class action relating to Spectre and Meltdown previously pending in Argentina, plaintiffs’ appeal of a May 2023 order dismissing their complaint for lack of standing was denied in February 2024, ending the lawsuit. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. Given the procedural posture and the nature of these cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these matters. Litigation Related to 7nm Product Delay Announcement Multiple securities class action lawsuits were filed in the US District Court for the Northern District of California against us and certain officers following our July 2020 announcement of 7nm product delays. The court consolidated the lawsuits and appointed lead plaintiffs in October 2020, and in January 2021 plaintiffs filed a consolidated complaint. Plaintiffs purport to represent all persons who purchased or otherwise acquired our common stock from October 25, 2019 through October 23, 2020, and they generally allege that defendants violated the federal securities laws by making false or misleading statements about the timeline for 7nm products. In March 2023, the district court granted the defendants’ motion to dismiss the consolidated complaint, and in April 2023 entered judgment. Plaintiffs appealed, and on April 19, 2024 the Ninth Circuit affirmed the judgment; the Ninth Circuit’s ruling is subject to appeal. Given the procedural posture and the nature of the case, including that it is in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class being certified or the ultimate size of any class if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from the matter. In July 2021, we introduced a new process node naming structure, and the 7nm process is now called Intel 4. Litigation Related to Patent and IP Claims We have had IP infringement lawsuits filed against us, including but not limited to those discussed below. Most involve claims that certain of our products, services, and technologies infringe others' IP rights. Adverse results in these lawsuits may include awards of substantial fines and penalties, costly royalty or licensing agreements, or orders preventing us from offering certain features, functionalities, products, or services. As a result, we may have to change our business practices, and develop non-infringing products or technologies, which could result in a loss of revenue for us and otherwise harm our business. In addition, certain agreements with our customers require us to indemnify them against certain IP infringement claims, which can increase our costs as a result of defending such claims, and may require that we pay significant damages, accept product returns, or supply our customers with non-infringing products if there were an adverse ruling in any such claims. In addition, our customers and partners may discontinue the use of our products, services, and technologies, as a result of injunctions or otherwise, which could result in loss of revenue and adversely affect our business. VLSI Technology LLC v. Intel In October 2017, VLSI Technology LLC (VLSI) filed a complaint against us in the US District Court for the Northern District of California alleging that various Intel FPGA and processor products infringe eight patents VLSI acquired from NXP Semiconductors, N.V. (NXP). Intel prevailed on all eight patents and the court entered final judgment in April 2024. Further appeals are possible. In April 2019, VLSI filed three infringement suits against us in the US District Court for the Western District of Texas accusing various of our processors of infringement of eight additional patents it had acquired from NXP: ▪ The first Texas case went to trial in February 2021, and the jury awarded VLSI $1.5 billion for literal infringement of one patent and $675 million for infringement of another patent under the doctrine of equivalents. In April 2022, the court entered final judgment, awarding VLSI $2.1 billion in damages and approximately $162.3 million in pre-judgment and post-judgment interest. We appealed the judgment to the Federal Circuit Court of Appeals, including the court’s rejection of Intel’s claim to have a license from Fortress Investment Group’s acquisition of Finjan. The Federal Circuit Court heard oral argument in October 2023. In December 2023, the Federal Circuit reversed the finding of infringement as to the patent for which VLSI was awarded $675 million. The Federal Circuit affirmed the finding of infringement as to the patent for which VLSI had been awarded $1.5 billion, but vacated the damages award and sent the case back to the trial court for further damages proceedings on that patent. The Federal Circuit also ruled that Intel can advance the defense that it is licensed to VLSI’s patents. In December 2021 and January 2022 the Patent Trial and Appeal Board (PTAB) instituted Inter Partes Reviews (IPR) on the claims found to have been infringed in the first Texas case, and in May and June 2023 found all of those claims unpatentable; VLSI has appealed the PTAB’s decision. In March 2024, Intel filed a motion to stay the case pending appeals of the IPRs. In April 2024, Intel moved to add the defense that it is licensed to VLSI’s patents. ▪ The second Texas case went to trial in April 2021, and the jury found that we do not infringe the asserted patents. VLSI had sought approximately $3.0 billion for alleged infringement, plus enhanced damages for willful infringement. The court has not yet entered final judgment. ▪ The third Texas case went to trial in November 2022, with VLSI asserting one remaining patent. The jury found the patent valid and infringed, and awarded VLSI approximately $949 million in damages, plus interest and a running royalty. The court has not yet entered final judgment. In February 2023, we filed motions for a new trial and for judgment as a matter of law notwithstanding the verdict on various grounds. Further appeals are possible. In April 2024, Intel moved to add the defense that it is licensed to VLSI’s patents. In May 2019, VLSI filed a case in Shenzhen Intermediate People’s Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserted one patent against certain Intel Core processors. Defendants filed an invalidation petition in October 2019 with the China National Intellectual Property Administration (CNIPA) which held a hearing in September 2021. The Shenzhen court held trial proceedings in July 2021, and September 2023. VLSI sought an injunction as well as RMB 1.3 million in costs and expenses, but no damages. In September 2023, the CNIPA invalidated every claim of the asserted patent. In November 2023, the trial court dismissed VLSI’s case. In May 2019, VLSI filed a case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. asserting one patent against certain Intel core processors. The court held a trial hearing in December 2020, where VLSI requested expenses (RMB 300 thousand) and an injunction. In December 2022, we filed a petition to invalidate the patent at issue. The court held a second trial hearing in May 2022, and in October 2023, issued a decision finding no infringement and dismissing all claims. In November 2023, VLSI appealed the finding of non-infringement. As of March 30, 2024, we have accrued a charge of approximately $1.0 billion related to the VLSI litigation. While we dispute VLSI’s claims and intend to vigorously defend against them, we are unable to make a reasonable estimate of losses in excess of recorded amounts given recent developments and future proceedings. R2 Semiconductor Patent Litigation In November 2022, R2 Semiconductor, Inc. (R2) filed a lawsuit in the High Court of Justice in the UK against Intel Corporation (UK) Limited and Intel Corporation, and a lawsuit in the Dusseldorf Regional Court in Germany against Intel Deutschland GmbH and certain Intel customers. R2 asserts one European patent is infringed by Intel’s Ice Lake, Tiger Lake, Alder Lake and Ice Lake Server (Xeon) processors (the accused products), and customer servers and laptops that contain those processors. R2 seeks an injunction in both actions prohibiting the sale and requiring the recall of the alleged infringing products. Intel is indemnifying its customers in the German lawsuit. Intel disputes R2’s claims and intends to defend the lawsuits vigorously. In December 2022, Intel responded in the UK action that the asserted patent is not infringed and that the patent is invalid. In April 2023, defendants filed statements of defense in the German action that the asserted patent is not infringed and that an injunction would be a disproportionate remedy. In May 2023, defendants also filed a nullity action in the German Federal Patent Court on the ground that the asserted patent is invalid. In December 2023, the German Federal Patent Court issued a preliminary opinion finding R2’s patent valid. The German Federal Patent Court’s final decision on invalidity is expected in October 2024. In December 2023, the court in Dusseldorf held a trial on the issue of infringement. In February 2024, the court found Intel’s processors infringe and issued an injunction and recall order against Intel and its customers. R2 has not yet sought to enforce the order. Intel has appealed the decision. In April 2024, Intel also filed a complaint with the Constitutional Court seeking a stay and a reversal of the finding of infringement and filed additional evidence with the appeals court to demonstrate that it does not infringe R2’s patent. In March 2024, Intel filed an action in Milan, Italy seeking an order that it does not infringe R2’s patent. In April 2024, R2 filed an action against Intel and its customers Dell, HP, and HPE for patent infringement in Paris, France. Intel and its customers have filed a nullity action against the patent in France. Trial in the UK matter is scheduled for April 2024. We are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from these lawsuits and the injunction and order of the Dusseldorf Regional Court due to the procedural posture and the nature of these cases, including that there are significant factual and legal issues to be resolved and that uncertainty exists as to, among other things: (i) whether and, if so, at what point in time the order in Germany may take effect, including as a result of a potential stay; (ii) whether and, if so, at what point we may be successful in appealing the decisions in Germany as to infringement and validity, (iii) the extent to which we and our customers are able to mitigate the impact of the injunction of the Dusseldorf Regional Court, (iv) the costs of recalling products if the recall order of the Dusseldorf Regional Court is enforced, (v) the extent to which R2 may be awarded damages, and (vi) the extent to which we may agree to compensate our customers for losses in connection with the injunction and recall and any potential damage award.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (381)	$ (2,758)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Operating Segments (Tables)

Operating Segments (Tables)	3 Months Ended
	Mar. 30, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Operating segment and consolidated net revenue and operating income (loss) for each period were as follows: Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Operating segment revenue: Intel Products: Client Computing Group Desktop $ 2,461 $ 1,879 Notebook 4,681 3,407 Other 391 481 7,533 5,767 Data Center and AI 3,036 2,901 Network and Edge 1,364 1,489 Total Intel Products revenue $ 11,933 $ 10,157 Intel Foundry $ 4,369 $ 4,831 All other Altera 342 816 Mobileye 239 458 Other 194 166 Total all other revenue 775 1,440 Total operating segment revenue $ 17,077 $ 16,428 Intersegment eliminations (4,353) (4,713) Total net revenue $ 12,724 $ 11,715 Segment operating income (loss): Intel Products: Client Computing Group $ 2,645 $ 1,180 Data Center and AI 482 22 Network and Edge 184 (69) Total Intel Products operating income (loss) $ 3,311 $ 1,133 Intel Foundry $ (2,474) $ (2,360) All Other Altera (39) 290 Mobileye (68) 123 Other (105) (66) Total all other operating income (loss) (212) 347 Total segment operating income (loss) $ 625 $ (880) Intersegment eliminations 494 456 Corporate unallocated expenses (2,188) (1,044) Total operating income (loss) $ (1,069) $ (1,468) Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Acquisition-related adjustments $ (265) $ (371) Share-based compensation (1,179) (739) Restructuring and other charges (348) (64) Other (396) 130 Total corporate unallocated expenses $ (2,188) $ (1,044)

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	3 Months Ended
	Mar. 30, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interests	Mar 30, 2024 Dec 30, 2023 (In Millions) Non-Controlling Interests Non-Controlling Ownership % Non-Controlling Interests Non-Controlling Ownership % Arizona Fab LLC $ 2,760 49 % $ 2,359 49 % Mobileye 1,854 12 % 1,838 12 % IMS Nanofabrication 169 32 % 178 32 % Non-controlling interests $ 4,783 $ 4,375

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 30, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended (In Millions, Except Per Share Amounts) Mar 30, 2024 Apr 1, 2023 Net income (loss) $ (437) $ (2,768) Less: Net income (loss) attributable to non-controlling interests (56) (10) Net income (loss) attributable to Intel (381) (2,758) Weighted average shares of common stock outstanding—basic 4,242 4,154 Weighted average shares of common stock outstanding—diluted 4,242 4,154 Earnings (loss) per share attributable to Intel—basic $ (0.09) $ (0.66) Earnings (loss) per share attributable to Intel—diluted $ (0.09) $ (0.66)

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	3 Months Ended
	Mar. 30, 2024
Other Financial Statement Details [Abstract]
Schedule of Inventory, Current [Table Text Block]	(In Millions) Mar 30, 2024 Dec 30, 2023 Raw materials $ 1,209 $ 1,166 Work in process 6,560 6,203 Finished goods 3,725 3,758 Total inventories $ 11,494 $ 11,127
Interest and Other, Net [Table Text Block]	Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Interest income $ 323 $ 334 Interest expense (258) (193) Other, net 80 — Total interest and other, net $ 145 $ 141

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	3 Months Ended
	Mar. 30, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Charges	Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Employee severance and benefit arrangements $ 129 $ (39) Litigation charges and other — 77 Asset impairment charges 219 26 Total restructuring and other charges $ 348 $ 64

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Provision for Income Tax and Effective Tax Rate	Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Income (loss) before taxes $ (719) $ (1,158) Provision for (benefit from) taxes $ (282) $ 1,610 Effective tax rate 39.2 % (139.0) %

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair value of marketable debt investments, by contractual maturity, as of March 30, 2024, was as follows: (In Millions) Fair Value Due in 1 year or less $ 5,579 Due in 1–2 years 2,457 Due in 2–5 years 6,915 Due after 5 years 433 Instruments not due at a single maturity date 1 2,460 Total $ 17,844 1
Investment [Table Text Block]	(In Millions) Mar 30, 2024 Dec 30, 2023 Marketable equity securities 1 $ 1,471 $ 1,194 Non-marketable equity securities 4,664 4,630 Equity method investments 4 5 Total $ 6,139 $ 5,829 1 Approximately 90% of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Ongoing mark-to-market adjustments on marketable equity securities $ (91) $ 188 Observable price adjustments on non-marketable equity securities 24 10 Impairment charges (69) (36) Sale of equity investments and other 1 341 7 Total gains (losses) on equity investments, net $ 205 $ 169 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions.

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Mar 30, 2024 Dec 30, 2023 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 231 $ — $ 231 $ — $ 769 $ — $ 769 Financial institution instruments¹ 2,438 787 — 3,225 2,241 835 — 3,076 Reverse repurchase agreements — 2,370 — 2,370 — 2,554 — 2,554 Short-term investments: Corporate debt — 6,298 — 6,298 — 6,951 — 6,951 Financial institution instruments¹ 22 3,777 — 3,799 33 4,215 — 4,248 Government debt² — 4,291 — 4,291 — 6,756 — 6,756 Other current assets: Derivative assets 34 739 — 773 366 809 — 1,175 Marketable equity securities 1,471 — — 1,471 1,194 — — 1,194 Other long-term assets: Derivative assets — 6 — 6 — 21 — 21 Total assets measured and recorded at fair value $ 3,965 $ 18,499 $ — $ 22,464 $ 3,834 $ 22,910 $ — $ 26,744 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 375 $ 118 $ 493 $ — $ 541 $ 99 $ 640 Other long-term liabilities: Derivative liabilities — 611 — 611 — 479 — 479 Total liabilities measured and recorded at fair value $ — $ 986 $ 118 $ 1,104 $ — $ 1,020 $ 99 $ 1,119 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, commercial paper, notes and bonds issued by financial institutions. 2 Level 2 investments consist primarily of non-US government debt.

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 30, 2024
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Mar 30, 2024 Dec 30, 2023 Foreign currency contracts $ 27,942 $ 30,064 Interest rate contracts 18,611 18,363 Other 2,507 2,103 Total $ 49,060 $ 50,530 The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of March 30, 2024 and December 30, 2023.
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Mar 30, 2024 Dec 30, 2023 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 69 $ 307 $ 255 $ 142 Interest rate contracts — 723 — 578 Total derivatives designated as hedging instruments $ 69 $ 1,030 $ 255 $ 720 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 391 $ 65 $ 314 $ 363 Interest rate contracts 285 9 261 36 Equity contracts 34 — 366 — Total derivatives not designated as hedging instruments $ 710 $ 74 $ 941 $ 399 Total derivatives $ 779 $ 1,104 $ 1,196 $ 1,119 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Mar 30, 2024 Dec 30, 2023 Mar 30, 2024 Dec 30, 2023 Long-term debt $ (11,275) $ (11,419) $ 722 $ 578
Offsetting Assets [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Mar 30, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 632 $ — $ 632 $ (350) $ (282) $ — Reverse repurchase agreements 2,370 — 2,370 — (2,370) — Total assets $ 3,002 $ — $ 3,002 $ (350) $ (2,652) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,097 $ — $ 1,097 $ (350) $ (620) $ 127 Total liabilities $ 1,097 $ — $ 1,097 $ (350) $ (620) $ 127 Dec 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95
Offsetting Liabilities [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Mar 30, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 632 $ — $ 632 $ (350) $ (282) $ — Reverse repurchase agreements 2,370 — 2,370 — (2,370) — Total assets $ 3,002 $ — $ 3,002 $ (350) $ (2,652) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,097 $ — $ 1,097 $ (350) $ (620) $ 127 Total liabilities $ 1,097 $ — $ 1,097 $ (350) $ (620) $ 127 Dec 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended (In Millions) Location of Gains (Losses) Mar 30, 2024 Apr 1, 2023 Foreign currency contracts Interest and other, net $ 346 $ 1 Interest rate contracts Interest and other, net 117 (34) Other Various 137 115 Total $ 600 $ 82
Interest and other, net [Member] | Fair Value Hedging
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended (In Millions) Mar 30, 2024 Apr 1, 2023 Interest rate contracts $ (144) $ 192 Hedged items 144 (192) Total $ — $ —

Operating Segments - Narrative

Operating Segments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Segment Reporting Information [Line Items]
Revenue from external customers	$ 12,724	$ 11,715
Goodwill impairment loss	222
Operating segments
Segment Reporting Information [Line Items]
Revenue from external customers	17,077	16,428
Operating segments | Intel Foundry
Segment Reporting Information [Line Items]
Revenue from external customers	4,369	4,831
Operating segments | Intel Foundry | Assembly And Test
Segment Reporting Information [Line Items]
Revenue from external customers	27	118
Operating segments | Other
Segment Reporting Information [Line Items]
Revenue from external customers	$ 194	$ 166

Operating Segments - Net Revenu

Operating Segments - Net Revenue and Operating Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Segment Reporting Information [Line Items]
Net revenue	$ 12,724	$ 11,715
Operating income (loss)	(1,069)	(1,468)
Operating segments
Segment Reporting Information [Line Items]
Net revenue	17,077	16,428
Operating income (loss)	625	(880)
Operating segments | Intel Products
Segment Reporting Information [Line Items]
Net revenue	11,933	10,157
Operating income (loss)	3,311	1,133
Operating segments | Client Computing
Segment Reporting Information [Line Items]
Net revenue	7,533	5,767
Operating income (loss)	2,645	1,180
Operating segments | Client Computing | Desktop
Segment Reporting Information [Line Items]
Net revenue	2,461	1,879
Operating segments | Client Computing | Notebook
Segment Reporting Information [Line Items]
Net revenue	4,681	3,407
Operating segments | Client Computing | Other
Segment Reporting Information [Line Items]
Net revenue	391	481
Operating segments | Datacenter and AI
Segment Reporting Information [Line Items]
Net revenue	3,036	2,901
Operating income (loss)	482	22
Operating segments | Network and Edge
Segment Reporting Information [Line Items]
Net revenue	1,364	1,489
Operating income (loss)	184	(69)
Operating segments | Intel Foundry
Segment Reporting Information [Line Items]
Net revenue	4,369	4,831
Operating income (loss)	(2,474)	(2,360)
Operating segments | All Other
Segment Reporting Information [Line Items]
Net revenue	775	1,440
Operating income (loss)	(212)	347
Operating segments | Altera
Segment Reporting Information [Line Items]
Net revenue	342	816
Operating income (loss)	(39)	290
Operating segments | Mobileye
Segment Reporting Information [Line Items]
Net revenue	239	458
Operating income (loss)	(68)	123
Operating segments | Other
Segment Reporting Information [Line Items]
Net revenue	194	166
Operating income (loss)	(105)	(66)
Intersegment eliminations
Segment Reporting Information [Line Items]
Net revenue	(4,353)	(4,713)
Operating income (loss)	494	456
Corporate unallocated expenses
Segment Reporting Information [Line Items]
Operating income (loss)	$ (2,188)	$ (1,044)

Operating Segments - Corporate

Operating Segments - Corporate Unallocated Expenses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Segment Reporting Information [Line Items]
Restructuring and other charges	$ (348)	$ (64)
Operating income (loss)	(1,069)	(1,468)
Corporate unallocated expenses
Segment Reporting Information [Line Items]
Acquisition-related adjustments	(265)	(371)
Share-based compensation	(1,179)	(739)
Restructuring and other charges	(348)	(64)
Other	(396)	130
Operating income (loss)	$ (2,188)	$ (1,044)

Non-Controlling Interests - Com

Non-Controlling Interests - Components (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Noncontrolling Interest [Line Items]
Non-controlling interest	$ 4,783	$ 4,375
Arizona Fab LLC
Noncontrolling Interest [Line Items]
Non-controlling interest	2,760	2,359
Mobileye
Noncontrolling Interest [Line Items]
Non-controlling interest	1,854	1,838
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Non-controlling interest	$ 169	$ 178
Arizona Fab LLC
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	49%	49%
Mobileye
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	12%	12%
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	32%	32%

Non-Controlling Interests - Nar

Non-Controlling Interests - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 30, 2024	Dec. 30, 2023
Noncontrolling Interest [Line Items]
Assets	$ 192,733	$ 191,572
Variable Interest Entity, Primary Beneficiary | Asset Pledged as Collateral
Noncontrolling Interest [Line Items]
Assets	5,600	$ 4,800
Mobileye
Noncontrolling Interest [Line Items]
Conversion of stock, shares converted (in shares)		38,500,000
Conversion of stock, shares converted, percentage of outstanding shares		0.05
Shares issued per share (in dollars per share)		$ 42
Net proceeds		$ 1,600
Mobileye | Capital in excess of par value
Noncontrolling Interest [Line Items]
Net proceeds from partner contributions		663
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares		1,400
IMS Nanofabrication | Capital in excess of par value
Noncontrolling Interest [Line Items]
Net proceeds from partner contributions		$ 958
Semiconductor Co-Investment Program, Construction Costs | Intel and Brookfield
Noncontrolling Interest [Line Items]
Unrecognized commitment	$ 29,000
Arizona Fab LLC
Noncontrolling Interest [Line Items]
Percentage of factory output with the right to purchase	100%
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Ownership percentage sold		32%
IMS Nanofabrication | Bain Capital Special Situations
Noncontrolling Interest [Line Items]
Ownership percentage sold		20%
IMS Nanofabrication | TSMC
Noncontrolling Interest [Line Items]
Ownership percentage sold		10%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Earnings Per Share [Abstract]
Net income (loss)	$ (437)	$ (2,768)
Less: Net income (loss) attributable to non-controlling interests	(56)	(10)
Net income (loss) attributable to Intel	$ (381)	$ (2,758)
Weighted average shares of common stock outstanding—basic	4,242	4,154
Weighted average shares of common stock outstanding—diluted	4,242	4,154
Earnings per share - Basic (in dollars per share)	$ (0.09)	$ (0.66)
Earnings per share - Diluted (in dollars per share)	$ (0.09)	$ (0.66)

Other Financial Statement Det_3

Other Financial Statement Details - Accounts Receivable (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Other Financial Statement Details [Abstract]
Accounts receivable sold	$ 500	$ 500

Other Financial Statement Det_4

Other Financial Statement Details - Inventories (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Other Financial Statement Details [Abstract]
Raw materials	$ 1,209	$ 1,166
Work in process	6,560	6,203
Finished goods	3,725	3,758
Total inventories	$ 11,494	$ 11,127

Other Financial Statement Det_5

Other Financial Statement Details - Other Accrued Liabilities (Details) - USD ($) $ in Billions	Mar. 30, 2024	Dec. 30, 2023
Other Financial Statement Details [Abstract]
Deferred compensation	$ 2.9	$ 2.9

Other Financial Statement Det_6

Other Financial Statement Details - Interest and Other, Net (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Other Financial Statement Details [Abstract]
Interest income	$ 323	$ 334
Interest expense	(258)	(193)
Other, net	80	0
Total interest and other, net	145	141
Interest Costs Capitalized	$ (363)	$ (363)

Other Financial Statement Det_7

Other Financial Statement Details - Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Change in Accounting Estimate [Line Items]
Increase to gross margin	$ 5,217	$ 4,008
Decrease in R&D expenses	(4,382)	$ (4,109)
Decrease in ending inventory	$ (11,494)		$ (11,127)

Restructuring and Other Charg_3

Restructuring and Other Charges - Components (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Restructuring and Related Activities [Abstract]
Employee severance and benefit arrangements	$ 129	$ (39)
Litigation charges and other	0	77
Asset impairment charges	219	26
Restructuring and other charges	$ 348	$ 64

Restructuring and Other Charg_4

Restructuring and Other Charges - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Loss Contingencies [Line Items]
Restructuring and other charges	$ 348	$ 55
Goodwill impairment loss	222
Charge (benefit) recorded in litigation charges and other	0	$ 77
2022 Restructuring Program
Loss Contingencies [Line Items]
Restructuring and other charges	$ 129

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Income Tax Disclosure [Abstract]
Income (loss) before taxes	$ (719)	$ (1,158)
Provision for (benefit from) taxes	$ (282)	$ 1,610
Effective tax rate	39.20%	(139.00%)

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($)	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt Securities, Realized Gain (Loss)	$ 307,000,000	$ 90,000,000
Debt Securities, Available-for-sale, Amortized Cost	4,000,000,000		$ 4,700,000,000
Available-for-sale Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative, Amount of Hedged Item	13,800,000,000		$ 17,100,000,000
Unrealized Gain (Loss) on Derivatives	$ 345,000,000	$ 102,000,000

Investments - Available-for-Sal

Investments - Available-for-Sale Debt Investments (Details) $ in Millions	Mar. 30, 2024 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in 1 year or less	$ 5,579
Due in 1–2 years	2,457
Due in 2–5 years	6,915
Due after 5 years	433
Instruments not due at a single maturity date	2,460
Debt Securities, Available-for-Sale, Total	$ 17,844

Investments - Equity Investment

Investments - Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	$ 1,471		$ 1,194
Cost Method Investments	4,664		4,630
Equity Method Investments	4		5
Equity Investments	$ 6,139		$ 5,829
Marketable equity securities subject to trading-volume or market-based restrictions	90%
Marketable equity securities threshold percentage of shares owned resulting in trading volume restrictions	1%
Mark to market on marketable equity securities1	$ (91)	$ 188
Observable price adjustments on non-marketable	24	10
Impairments	(69)	(36)
Other Net Equity Investments	341	7
Gain (Loss) on Investments	$ 205	$ 169

Investments - Equity Investme_2

Investments - Equity Investments, Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Schedule of Equity Method Investments [Line Items]
Special dividend recognized in sale of equity investments and other	$ 341	$ 7

Investments - Bejing Unisoc Tec

Investments - Bejing Unisoc Technology (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	$ 205	$ 169

Divestitures (Details)

Divestitures (Details) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Business Acquisition [Line Items]
Receivable recorded in other current assets	$ 6,480	$ 3,706
NAND Memory Business Divestiture | Affiliated Entity
Business Acquisition [Line Items]
Receivable recorded in other current assets	150	$ 145
NAND Memory Business
Business Acquisition [Line Items]
Noncurrent receivable	2,000
Maximum exposure annually	500
Maximum exposure	$ 1,500

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($)	3 Months Ended
	Apr. 01, 2023	Mar. 30, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Commercial paper outstanding		$ 793,000,000	$ 0
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity		10,000,000,000
Revolving Credit Facility | Variable Rate Revolving Credit Facility
Debt Instrument [Line Items]
Term of debt	5 years
Maximum borrowing capacity	$ 7,000,000,000		5,000,000,000
Variable rate revolving credit facility		0
Senior Notes
Debt Instrument [Line Items]
Face amount of debt		2,600,000,000
Line of Credit | Credit Facility Agreement
Debt Instrument [Line Items]
Term of debt	364 days
Maximum borrowing capacity	$ 8,000,000,000		$ 5,000,000,000
Variable rate revolving credit facility		$ 0

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	Mar. 30, 2024	Dec. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	$ 2,370	$ 2,554
Derivative assets, Fair Value Disclosure	632	1,047
Derivative liabilities, Fair Value Disclosure	1,097	1,111
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	22,464	26,744
Liabilities, Fair Value Disclosure	1,104	1,119
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants & loans Receivable, Reverse repurchase agreements, CV	666	559
Short-term and Long-term Debt, Fair Value	48,700	47,600
Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,471	1,194
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	2,370	2,554
Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	231	769
Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,225	3,076
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,298	6,951
Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,799	4,248
Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,291	6,756
Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	773	1,175
Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	6	21
Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	493	640
Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	611	479
Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	3,965	3,834
Liabilities, Fair Value Disclosure	0	0
Level 1 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,471	1,194
Level 1 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,438	2,241
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	22	33
Level 1 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	34	366
Level 1 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 1 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	18,499	22,910
Liabilities, Fair Value Disclosure	986	1,020
Level 2 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 2 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	2,370	2,554
Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	231	769
Level 2 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	787	835
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,298	6,951
Level 2 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,777	4,215
Level 2 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,291	6,756
Level 2 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	739	809
Level 2 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	6	21
Level 2 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	375	541
Level 2 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	611	479
Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	118	99
Level 3 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 3 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	118	99
Level 3 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	$ 0	$ 0

Derivative Financial Instrume_3

Derivative Financial Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Notional Disclosures [Abstract]
Notional amount	$ 49,060		$ 50,530
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	632		1,047
Derivative Assets Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0
Derivative Assets Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	632		1,047
Derivative Assets, Financial Instruments Not Offset in the Balance Sheet	(350)		(617)
Derivative Assets, Cash Collateral Not Offset in the Balance Sheet	(282)		(430)
Derivative Assets Subject to Master Netting Arrangements, Net Amount	0		0
Reverse Repurchase Agreements, Gross Amounts Recognized	2,370		2,554
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0		0
Reverse Repurchase Agreements, Net Amount Presented in the Balance Sheet	2,370		2,554
Reverse Repurchase Agreements, Financial Instruments Not Offset in the Balance Sheet	0		0
Reverse Repurchase Agreements, Cash Collateral Not Offset in the Balance Sheet	(2,370)		(2,554)
Reverse Repurchase Agreements, Net Amount	0		0
Total Assets, Gross Amounts Recognized	3,002		3,601
Total Assets, Gross Amounts Offset in the Balance Sheet	0		0
Total Assets, Net Amounts Presented in the Balance Sheet	3,002		3,601
Total Assets, Financial Instruments, Not Offset in the Balance Sheet	(350)		(617)
Total Assets, Cash and Non Cash Collateral, Not Offset in the Balance Sheet	(2,652)		(2,984)
Total Assets, Net Amount	0		0
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,097		1,111
Derivative Liabilities Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,097		1,111
Derivative Liabilities, Financial Instruments Not Offset in the Balance Sheet	(350)		(617)
Derivative Liabilities, Cash Collateral Not Offset in the Balance Sheet	(620)		(399)
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount	127		95
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	144	$ (192)
Net Change In Unrealized Gain (Loss) Recognized In Income Statement On Fair Value Hedging Instruments And On Hedged Item In Fair Value Hedge	0	0
Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	779		1,196
Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,104		1,119
Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	69		255
Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	1,030		720
Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	600	82
Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	710		941
Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	74		399
Foreign currency contracts
Notional Disclosures [Abstract]
Notional amount	27,942		30,064
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net [Abstract]
Before-tax net gains (losses) attributed to cash flow hedges, recognized in other comprehensive income (loss)	(431)	53
Foreign currency contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	69		255
Foreign currency contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	307		142
Foreign currency contracts | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	346	1
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	391		314
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	65		363
Interest rate contracts
Notional Disclosures [Abstract]
Notional amount	18,611		18,363
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(144)	192
Interest rate contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	0		0
Interest rate contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	723		578
Interest rate contracts | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	117	(34)
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	285		261
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	9		36
Other
Notional Disclosures [Abstract]
Notional amount	2,507		2,103
Other | Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	137	$ 115
Other | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	34		366
Other | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	0		0
Interest Rate Swap | Long-term Debt | Fair Value Hedging
Derivative [Line Items]
Derivative, Amount of Hedged Item	12,000
Derivative, Fair Value, Net	(11,275)		(11,419)
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	$ 722		$ 578

Contingencies (Detail)

Contingencies (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023	Dec. 30, 2023
Loss Contingencies [Line Items]
Litigation charges and other	$ 0	$ 77
Finance lease prepayments	0	$ 15
EC Fine
Loss Contingencies [Line Items]
Estimated Litigation Liability	401
VLSI Litigation
Loss Contingencies [Line Items]
Estimated Litigation Liability	$ 1,000
Arizona Fab LLC
Loss Contingencies [Line Items]
Non-controlling interest percent held by parent	49%		49%